.png "Sarepta Therapeutics Received its Third Buy in a Row")
After Robert W. Baird and Nomura gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares opened today at $160, close to its 52-week high of $176.50.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 3.0% and a 49.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is Strong Buy and the average price target is $104.57, representing a -34.6% downside.
In a report issued on June 15, BTIG also initiated coverage with a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $32.36. Currently, Sarepta Therapeutics has an average volume of 1.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
